Vyteris - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 40
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: V3C9FA64805EN
Leaflet:

Download PDF Leaflet

Summary

Global Market Direct’s pharmaceuticals report, “Vyteris - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.

Scope

- Vyteris - company overview including business description, key employees, and other facts.
- Review of current pipeline of Vyteris human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Vyteris with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Vyteris’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Vyteris’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Vyteris in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Vyteris’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Vyteris.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Vyteris and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 list of Figures

2 INTRODUCTION
3 VYTERIS SNAPSHOT

3.1 Business Description

4 VYTERIS- RESEARCH AND DEVELOPMENT OVERVIEW

4.1 Key Therapeutic Areas

5 VYTERIS- PIPELINE REVIEW

5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities

6 VYTERIS PIPELINE PRODUCTS GLANCE

6.1 Vyteris Phase II Pipeline
6.2 Vyteris Phase I Pipeline
6.3 Vyteris Pre-Clinical Pipeline

7 VYTERIS - DRUG PROFILES

7.1 Product
  7.1.1 Product Description
  7.1.2 Mechanism of Action
  7.1.3 R&D Progress

8 VYTERIS PIPELINE ANALYSIS

8.1 Vyteris Pipeline Products by Therapeutic Class
8.2 Vyteris Pipeline Products by Target
8.3 Vyteris Pipeline by Route of Administration
8.4 Vyteris Pipeline Products by Molecule Type

9 VYTERIS- RECENT PIPELINE UPDATES
10 VYTERIS- DORMANT PIPELINE PROJECTS

10.1 Feature on Dormant Projects

11 VYTERIS- DISCONTINUED PIPELINE PRODUCTS

11.1 Discontinued Pipeline Product Profiles
  11.1.1 Product

12 VYTERIS – FEATURED NEWS
13 VYTERIS STATEMENT

13.1 Vyteris - Locations and Subsidiaries

14 APPENDIX

14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer

LIST OF TABLES

Table 1: Vyteris - Key Information
Table 2: Vyteris - Key Facts
Table 3: Vyteris - Key Therapeutic Areas
Table 4: Vyteris - Pipeline by Stage of Development,
Table 5: Vyteris - Monotherapy Products in Pipeline,
Table 6: Vyteris - Combination Treatment Modalities in Pipeline,
Table 7: Vyteris - Phase II Pipeline,
Table 8: Vyteris - Phase I Pipeline,
Table 9: Vyteris - Pre-Clinical Pipeline,
Table 10: Vyteris - Pipeline By Therapeutic Class
Table 11: Vyteris - Pipeline By Target
Table 12: Vyteris - Pipeline By Route of Administration
Table 13: Vyteris - Pipeline By Molecule Type
Table 14: Vyteris - Recent Pipeline Updates
Table 15: Vyteris - Dormant Pipeline Projects

LIST OF FIGURES

Figure 1: Vyteris - Research and Development Overview
Figure 2: Vyteris - Pipeline by Stage of Development,
Figure 3: Vyteris - Monotherapy Products in Pipeline,
Figure 4: Vyteris - Combination Treatment Modalities in Pipeline,
Figure 5: Vyteris - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Vyteris - Pipeline By Therapeutic Class
Figure 7: Vyteris - Pipeline By Target and Stage of Development
Figure 8: Vyteris - Pipeline By Target
Figure 9: Vyteris - Pipeline By Route of Administration and Stage of Development
Figure 10: Vyteris - Pipeline By Route of Administration
Figure 11: Vyteris - Pipeline By Molecule Type and Stage of Development
Figure 12: Vyteris - Pipeline By Molecule Type

COMPANIES MENTIONED

Vyteris

Ask Your Question

Vyteris - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: